Randomized clinical trial: Effect of lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome

Nutrition

Volumn 30, Issue 10, 2014, Pages 1151-1157

  Stevenson, Cheryl ^a   Blaauw, Renée ^a   Fredericks, Ernst ^b   Visser, Janicke ^a   Roux, Saartjie ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

Author keywords

Irritable bowel syndrome; Lactobacillus plantarum 299 v; Probiotics

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIUM IDENTIFICATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY ASSESSMENT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; IRRITABLE COLON; LACTOBACILLUS PLANTARUM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYNDROME DELINEATION; DOUBLE BLIND PROCEDURE; IRRITABLE BOWEL SYNDROME; TREATMENT OUTCOME;

LACTOBACILLUS PLANTARUM;

ABDOMINAL PAIN; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS PLANTARUM; MALE; MIDDLE AGED; PROBIOTICS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84926218903     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.02.010     Document Type: Article

References (37)

1. Veldhuyzen van Zanten SJO, Talley NJ. Design of treatment trials for functional gastrointestinal disorders. Gut 1999;45(Suppl):1169-77.
2. Rogers NJ, Mousa SA. The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. J Altern Complement Med 2012;18:112-9.
3. Brenner DM, Moeller MJ. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-49.
4. Change JY, Talley NJ. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment. Trends Pharmacol Sci 2010;31:326-34.
5. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101:1581-90.
6. Niedzielin K, Kordecki H. A controlled double-blind, randomised study on the efficacy of Lactobacillus plantarum 299 V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143-7.
7. Nobaek S, Johansson ML. Alteration of intestinal microflora associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8.
8. Sen S, Mullan MM. Effect of Lactobacillus plantarum 299 V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615-20.
9. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51.
10. Halpern GM, Prindiville T. Treatment of irritable bowel syndrome with Lacteol-Fort: a randomised, double blind, crossover trial. Am J Gastroenterol 1996;91:1579-850.
11. Kim HJ, Camilleri M, McKinzie S, et al. A randomised controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.
12. Kajander K, Hatakka K. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-mo intervention. Aliment Pharmacol Ther 2005;22:387-94.
13. Kajander K, Krogius-Kurikka L. Effects of multispecies probiotc supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:463-73.
14. Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, Rasmussen M, Järvenpää S, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilises intestinal microbiota. Aliment Pharmacol Ther 2008;27:48-57.
15. Kanmani P, Satish Kumar R, Yuvaraj N, Paari KA, Pattukumar V, Arul V. Probiotics and its functionally valuable productsda review. Crit Rev Food Sci Nutr 2013;53:641-58.
16. Johansson ML, Nobaek S, Berggren A, Nyman M, Björck I, Ahrné S, et al. Survival of Lactobacillus plantarum DSM 9843 (299 v), and effect on the short-chain fatty acid content of faeces after ingestion of a rose-hip drink fermented with oats. Int J Food Micro 1998;42:29-38.
17. Cook SI, Sellin JH. Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther 1998;12:499-507.
18. Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, et al. The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 1996;111:334-44.
19. Molin G. Probiotics in foods not containing milk or milk constituents, with special reference to Lactobacillus plantarum 299 v. Am J Clin Nutr 2001;73(Suppl):380S-5S.
20. Pathmakanthan S, Li CK. Lactobacillus plantarum 299 v: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 2004;19:166-73.
21. Dunne C, Murphy L, Flynn S, O'Mahony L, O'Halloran S, Feeney M, et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek 1999;76:279-92.
22. Dunne C, O'Mahony L, Murphy L, Thornton G, Morrissey D, O'Halloran S, et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 2001 Feb;73(2 Suppl):386S-92S.
23. Collins JK, Dunne C, Murphy L, Morrissey D, O'Mahony L, O'Sullivan E, et al. A randomised controlled trial of a probiotic Lactobacillus strain in healthy adults: assessment of its delivery, transit, and influence on microbial flora and enteric immunity. Microb Ecol Health Dis 2002;14:81-9.
24. Schultz M, Veltkamp C. Lactobacillus plantarum 299 V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 2002;8:71-80.
25. Johansson ML, Molin G. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonisation of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol 1993;59:15-20.
26. Patrick DL, Drossman DA, Frederick IO. A quality-of-life measure for persons with irritable bowel syndrome (IBS-QOL): user's manual and scoring diskette for United States Version. Seattle, WA: University of Washington; 1997.
27. Francis CY, Morris J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402.
28. Ducrotte P. Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299 v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012;18:4012-8.
29. Design of Treatment Trials CommitteeIrvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538-51.
30. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000;133:455-63.
31. Patel SM, Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988;95:232-41.
32. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32: 144-58.
33. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010;5:E15591.
34. Pitz M, Cheang M, Berstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3: 237-47.
35. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol 2007;7:30.
36. Jones R. Likely impacts of recruitment site and methodology on characteristics of enrolled patient population: irritable bowel syndrome clinical trial design. Am J Med 1999;107:85S-90S.
37. Longstreth GF, Hawkey CJ, Mayer EA, Jones RH, Naesdal J, Wilson IK, et al. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol Ther 2001;15:959-64.